|
ü¿ÜÁø´Ü ÀǾàǰ ºñÁö´Ï½º Àü¸Á
In Vitro Diagnostics Business Outlook
|
¸®¼Ä¡»ç |
Kalorama Information
|
¹ßÇàÁ¤º¸ |
¿¬°£±¸µ¶ |
»óǰÄÚµå |
1035040 |
ÆäÀÌÁö Á¤º¸ |
¿µ¹®
|
ü¿ÜÁø´Ü ÀǾàǰ ºñÁö´Ï½º Àü¸Á
In Vitro Diagnostics Business Outlook
|
¹ßÇàÁ¤º¸ : | ÆäÀÌÁö Á¤º¸ : ¿µ¹® |
|
|
¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹®¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù. ¼¼°èÀÇ Ã¼¿ÜÁø´Ü ÀǾàǰ ºñÁö´Ï½º(In Vitro Diagnostics Business) ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä¿Í ÇÔ²² ½ÃÀå ±Ô¸ð, Ä«Å×°í¸®º° Ãֽе¿Çâ, Áö¿ªº° ½ÃÀå µ¿Çâ ¹× ½ÃÀå¿¡ Âü¿©ÇÏ´Â ±â¾÷ °³¿ä µîÀ» Á¦°øÇÕ´Ï´Ù.
»ùÇà ºä
º¸°í¼ ³»¿ë
- ü¿ÜÁø´Ü ÀǾàǰ(IVD) ½ÃÀå ºÎ¹®º° ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø
- ÀÓ»óÈÇÐ, °¨¿°Áõ °Ë»ç, Á¾¾çÇÐ, Ç÷¾×ÇÐ, Ç÷¾×ÀºÇà, ÀÀ°í, POC(Point of Care) µî Áß¿äÇÑ °Ë»ç Ä«Å×°í¸®ÀÇ ÃֽŠÁ¤º¸
- ¾÷°è ¿öÄ¡ - COVID-19¸¦ ºñ·ÔÇÑ °Ë»ç µ¿Çâ
- M&A, À¯Åë, ÆÄÆ®³Ê½Ê ÃßÀû°ú ºÐ¼®
- ½ÅÁ¦Ç° ¼Ò°³¿Í ±â¾÷ ¹ßÇ¥
- ±â¾÷ °³¿ä¿Í ºÐ±âº° ½ÇÀû ¿ä¾à
- Áö¿ªº° ½ÃÀå Á¤º¸
KSM 21.11.15
From Kalorama Information and Science and Medicine Group (publishers of Instrument Business Outlook) comes a new publication focusing on the business of clinical testing.
SAMPLE VIEW
‘In Vitro Diagnostics Business Outlook’ offers the following:
- Market Sizing and Forecasting of IVD Market Segments in Every Issue
- Clinical Chemistry, Infectious Disease Testing, Oncology, Hematology, Blood Banking, Coagulation, Point of Care-Updates on the Important Test Categories You Need to Know About
- Industry Watch - Developments with COVID-19 and Other Testing
- M&A, Distribution, Partnerships Tracked and Charted
- New Product Introductions and Company Announcements
- Company Profiling and Quarterly Results Summaries
With issues 2x a month, this newsletter dedicated to In Vitro Diagnostics is the best way to keep up in this rapidly-developing and well financed field.
Finding markets with higher growth than the average is critical.
|

|
¼¼°èÀÇ Ã¼¿ÜÁø´Ü ½ÃÀå : ÄÄÆ÷³ÍÆ®º°, ±â¼úº°, ÃÖÁ¾»ç¿ëÀÚº°, ¾ÖÇø®ÄÉÀ̼Ǻ° ¿¹Ãø(-2026³â) - COVID-19ÀÇ ´©ÀûÀû ¿µÇâ
¼¼°èÀÇ Ã¼¿ÜÁø´Ü ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® : Á¦Ç°º°(½Ã¾à, ¼ºñ½º), °Ë»çÀå¼Òº°(PoC, ÀçÅÃÀÇ·á), ÃÖÁ¾ ¿ëµµº°(º´¿ø, °Ë»ç½Ç), ¿ëµµº°, ±â¼úº°, ºÎ¹®º° ¿¹Ãø(2022-2030³â)
¼¼°èÀÇ Ã¼¿ÜÁø´Ü(IVD) ½ÃÀå(2022³â)
¼¼°èÀÇ Ã¼¿ÜÁø´Ü¿ë ÀǾàǰ(IVD) Á¦ÈÞ °è¾à µ¿Çâ
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Ã¼¿ÜÁø´Ü(IVD) ½ÃÀå
ü¿ÜÁø´Ü¿ë(IVD) ºÐ¼® ÀåÄ¡ : ¼¼°è ½ÃÀå
¼¼°èÀÇ Ã¼¿ÜÁø´Ü(IVD) ½ÃÀå : ¿¹Ãø(2022-2027³â)
¼¼°èÀÇ Ã¼¿ÜÁø´Ü(IVD) ½ÃÀå ¿¹Ãø(-2026³â) : Á¦Ç° ¹× ¼ºñ½ºº°(±â±â, ŰƮ), ±â¼úº°(¸é¿ªºÐ¼®¹ý, MDx, Ç÷¾×°Ë»ç, ¼Òº¯°Ë»ç), ÀûÀÀÁõº°(´ç´¢º´, Á¾¾ç, ½ÉÀ庴, ½ÅÀ庴, °¨¿°Áõ), ÃÖÁ¾»ç¿ëÀÚº°
¼¼°èÀÇ Ã¼¿ÜÁø´Ü(IVD) ǰÁú°ü¸® ½ÃÀå(2021-2028³â)
¼¼°èÀÇ IVD ¼öŹ¿¬±¸±â°ü ½ÃÀå ¿¹Ãø - COVID-19ÀÇ ¿µÇâ°ú ºÐ¼® : Á¾·ùº°, ¼ºñ½ºº°, Áö¿ªº°(-2028³â)
|